Full Title: Multi-modular Chimeric Antigen Receptor T cells targeting B7-H3 in children, Teenage & Young adult sarcoma Cancer Paediatrics
Phase I Interventional
Status: Active, Recruiting
Age Range: 1 - 16 years old
Eligibility: Rhabdomyosarcoma, Ewing sarcoma or Desmoplastic small round cell tumours expressing the protein B7-H3, suffering from relapsed or refractory disease after one or multiple lines of previous treatment.
Locations: University College London Hospital.
Study number: ISRCTN75533638 . Furter information can be found here.
MIGHTY is part of the Cancer Grand Challenges NexTGen which is testing whether cutting-edge T cell therapy can help treat children and young people with solid tumours by harnessing their immune system. NexTGen is an international team co-funded by Cancer Research UK, the National Cancer Institute in the US and The Mark Foundation for Cancer Research. The team includes researchers across the UK, US and France, collaborating to explore new ways for a type of immunotherapy called CAR-T cell therapy to help children and young people.
MIGHTY utilises modified T-cells that can withstand the tumour microenvironment and recognise a protein called B7-H3, which is found on most solid tumours in children and young people.
By recognising this protein, the T-cells can bind to and kill the cancer cells.
To find out more about this study, please contact [email protected].
If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust.
Donate now (This link opens in a new window) More about Ewing sarcoma